Viking Therapeutics Inc (NASDAQ: VKTX ) stock is on a mad dash today, vaulting up 69% and earning price target boost from Maxim analyst Jason McCarthy. The source of the frenzy burning up Wall Street today? The biotech player unleashed positive 36-week data for Madrigal’s NASH asset MI-3196, a Thyroid Hormone Receptor Beta agonist (TRβ), the same class of drug as Viking’s 2809.
Notably, Phase 2 trial data in NAFLD/Hypercholesterolemia is anticipated in the back half of the year.Maxim Gets Even More Bullish on Viking Therapeutics (VKTX) on Back of Encouraging NASH Data Read-Out
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться